Citius Oncology定价900万美元;股价下跌逾5%

2025-09-09 20:42

Citius Oncology (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR), announced on Tuesday that it has entered into a securities purchase agreement with a single institutional investor to purchase 5.14 million shares of common stock in a registered direct offering.
In a concurrent private placement, the company also agreed to issue unregistered warrants to purchase up to an aggregate of 5.14 million shares of common stock.
The combined effective offering price for each share of common stock and accompanying warrant is $1.75. The warrants will have an exercise price of $1.84 per share, will be exercisable six months from the date of issuance, and will expire on the five and one-half year anniversary from the date of issuance.
The gross proceeds to the company from the registered direct offering and concurrent private placement are estimated to be approximately $9 million before deducting placement agent fees and other estimated offering expenses payable by the company.
The offering is expected to close on or about September 10, 2025.
CTXR -5.73% premarket to $1.15.
Source: Press Release

More on Citius Pharmaceuticals, Citius Oncology